Clinical trials: sponsored by Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The main questions it aims to answer are: 1. Does the combination of GP induction chemotherapy and toripalimab improve the 3-year progression-free survival (PFS) compared to GP induction chemotherapy with placebo? 2.
- Trial name
- Navigation (NCT06712888)
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- Where
- 10 sites in China
- Volunteers
- 466 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer(NSCLC)
Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
Patients with advanced non-small cell lung cancer (NSCLC) who experience disease progression after standard systemic therapies or are unable to tolerate such therapies have limited subsequent treatment options.
- Trial name
- NCT07738367
- Testing
- Bronchial Arterial Chemoembolization (BACE), Systemic anti-tumor combination medications
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer, Advanced Neoplasia
Development and Validation of a Colorectal Cancer Diagnostic Model
This is a multicenter, observational study designed to develop and validate a diagnostic model for colorectal cancer and advanced colorectal neoplasia among adults undergoing routine-care colonoscopy in the Chinese population.
- Conditions
- Colorectal Cancer, Advanced Neoplasia, Prediction Models, Risk Stratification
- Trial name
- NCT07692555
- Where
- 4 sites in China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
HR+/HER2- Breast Cancer, Breast Neoplasms
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
This study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in HR+/HER2…
- Trial name
- NCT07702708
- Testing
- Pre-treatment DCE-MRI-based AI model
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
Non Small Cell Lung Cancer
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
During the surgery for non-small cell lung cancer (NSCLC), lymphadenectomy or lobectomy are performed first, different surgeons have different choices.
- Trial name
- LOFTY (NCT06577792)
- Testing
- Lobectomy-First, Lymphadenectomy-First
- Where
- 26 sites in China
- Volunteers
- 620 people
- Sponsor
- Sun Yat-sen University
HR+/HER2- Breast Cancer, Breast Neoplasms
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
This study is a single-center, prospective, open-label exploratory clinical study to assess the efficacy and safety of kumorixilib combined with capecitabine and letrozole as neoadjuvant therapy in patients with HR+/HER2- stage…
- Trial name
- NCT07691333
- Testing
- Kumorixilib 180mg, Capecitabine 500mg, Letrozole 2.5mg
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Malignant Tumor
Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
The tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database.
- Trial name
- NCT04793672
- Testing
- Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
- Where
- 2 sites in China
- Volunteers
- 4,100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Gastric Cancer
Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with…
- Trial name
- DIAMC-GC (NCT07638631)
- Testing
- Ipilimumab injection N01, Sintilimab, Modified (60% standard dose) XELOX
- Volunteers
- 30 people
- Sponsor
- Chen Lizhu
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Thyroid Diseases, Thyroid Neoplasms
Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery
This study aims to evaluate the performance of the PTAIR computer vision model for recognizing parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery.
- Trial name
- PTAIR (NCT07628543)
- Testing
- PTAIR Computer Vision Model Assessment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Nasopharyngeal Carcinoma (NPC)
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
This study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- RAIRI-NPC (NCT07590024)
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 651 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma (NPC)
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
This prospective, multicenter, real-world observational study aims to evaluate whether a response-adapted individualized risk index, the RAIRI model, can identify patients with non-metastatic nasopharyngeal carcinoma who may or…
- Trial name
- NCT07618078
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hypersensitivity Reaction
A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers
This is a prospective clinical study enrolling eligible subjects scheduled to receive oxaliplatin-based chemotherapy after signing informed consent forms. Subjects are randomly assigned to two groups.
- Trial name
- NCT07613905
- Testing
- Oxaliplatin, Saline (0.9% NaCl)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Cervical Carcinoma
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
This study aims to compare the efficacy and safety of "neoadjuvant immunotherapy combined with chemotherapy followed by immunotherapy combined with radiotherapy during the radiotherapy period" versus "standard concurrent…
- Trial name
- NCT07613567
- Testing
- standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric or Gastroesophageal Junction Cancer
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to…
- Trial name
- NCT04053205
- Testing
- Gentuximab, Paclitaxel
- Where
- 12 sites in China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor
- Trial name
- NCT07584954
- Testing
- IUAb190708, a cytotoxic antibody
- Where
- 6 sites in China
- Volunteers
- 90 people
- Sponsor
- Jun Zhou
Breast Diseases, Breast Neoplasms
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2…
- Conditions
- Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
- Trial name
- NCT07581834
- Testing
- Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- 2 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Nutrition Therapy
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced…
- Trial name
- NCT04436965
- Testing
- Standardized nutrition therapy, Cisplatin, Intensity Modulated Radiation Therapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University